Lannett, Novitium to offer generic levorphanol

Press enter to search
Close search
Open Menu

Lannett, Novitium to offer generic levorphanol

By Sandra Levy - 07/28/2020

Lannett has entered into an exclusive U.S. distribution agreement for levorphanol tablets with Novitium Pharma. The product is the generic of Sentynl Therapeutics’ levorphanol tartrate tablets 2 mg.

Under the agreement, Lannett will primarily provide sales, marketing and distribution support for the product, for which it will receive a share of the profits. Other financial terms were not disclosed.

"We are pleased to establish a new strategic relationship with Novitium Pharma, a private company with a growing portfolio of commercial products," said Tim Crew, Lannett CEO. "Novitium received FDA approval earlier this month of its ANDA for levorphanol tablets 2 mg, a product currently with a small number of competitors. Levorphanol tablets 2 mg is a solid addition to our product offering."

Levorphanol tablets 2 mg had a market value of roughly $60.9 million, for the 12 months ended May 2020, according to IQVIA, although the company said actual generic market values are expected to be lower.

Related Topics